Alumis Inc
ALMSHealthcare|Biotechnology|USA
$28.32
-1.96 (-6.48%)
Tangible Book
$4.06
Upcoming Data Readouts (2)
Dec 2026
Est. completion
P2Plaque Psoriasis
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
NCT05739435n=165
Nov 2028
Est. completion
P3Plaque Psoriasis
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541n=1,680
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Jul 2026
P2
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
NCT05966480